ArticleProstate cancer and prostatic diseases2018

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.

Benjamin L Maughan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.